{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events to calculate confidence interval","groupId":"OG002","lowerLimit":"5.3","upperLimit":"NA","value":"21.3"},{"comment":"Insufficient number of participants with events Insufficient number of participants with events to calculate confidence interval","groupId":"OG003","lowerLimit":"8.1","upperLimit":"NA","value":"8.9"},{"comment":"Insufficient number of participants with events to calculate confidence interval","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"5.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Duration of response according to iRECIST was defined as time to disease progression for participants with partial response or complete response according to iRECIST for target lesions and assessed by CT/MRI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG000","title":"Part A (Nanrilkefusp Alfa Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose.","id":"OG001","title":"Part A1 (Nanrilkefusp Alfa Divided Dosing, Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.\n\nPembrolizumab 200 mg was administered intravenously on day 1 of the 21-day treatment cycle.","id":"OG002","title":"Part B (Nanrilkefusp Alfa Combined With Pembrolizumab)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG003","title":"Part D (Nanrilkefusp Alfa Monotherapy, Expansion at the RP2D Identified in Part A)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose. v","id":"OG004","title":"Part B1 (Nanrilkefusp Alfa Twice Daily With Pembrolizumab, Expansion at RP2D Identified in Part A)"}],"paramType":"MEDIAN","populationDescription":"Patients who were exposed to nanrilkefusp alfa for at least 1 cycle and with at least 1 evaluable tumor assessment per iRECIST after nanrilkefusp alfa treatment start were analyzed. In the trial protocol and SAP it was pre-specified that the arms in individual trial parts will be analyzed combined (A, A1, B, D, and B1).","reportingStatus":"POSTED","timeFrame":"Day 1 up to approximately 5 years 5 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}